卵巢早衰 中国就医指南

Premature Ovarian Insufficiency (POI), formerly known as premature ovarian failure, is a clinical syndrome characterized by the loss of ovarian function before age 40. It is defined by amenorrhea (absence of menstruation) for at least four consecutive months, elevated follicle-stimulating hormone (FSH) levels (>25 IU/L on two occasions >4 weeks apart), and low estradiol levels. Unlike natural menopause, POI is not always permanent—approximately 5–10% of affected individuals experience intermittent ovarian activity and even spontaneous pregnancy. Pathogenically, POI results from accelerated depletion or dysfunction of ovarian follicles due to diverse mechanisms: genetic abnormalities (e.g., X-chromosome anomalies like Turner syndrome or FMR1 premutation), autoimmune disorders (e.g., associated with thyroiditis or Addison’s disease), iatrogenic causes (chemotherapy, radiation, or ovarian surgery), metabolic conditions (e.g., galactosemia), infections (rare, e.g., mumps oophoritis), or idiopathic origins (accounting for ~75–90% of cases). Epidemiologically, POI affects approximately 1% of women under age 40, 0.1% under age 30, and 0.01% under age 20. Incidence appears consistent across ethnic groups, though underdiagnosis remains common due to symptom variability and lack of routine screening. Key risk factors include family history of POI or early menopause, prior gonadotoxic treatments, autoimmune polyglandular syndromes, certain chromosomal disorders, and smoking (which may accelerate follicular atresia). Beyond reproductive implications—infertility being the most distressing consequence—POI significantly impacts long-term health and quality of life. Estrogen deficiency increases risks of osteoporosis, cardiovascular disease, cognitive decline, and genitourinary syndrome of menopause (vaginal atrophy, dyspareunia, urinary urgency). Psychologically, patients frequently report anxiety, depression, diminished self-esteem, sexual dysfunction, and grief over lost fertility and altered life trajectory. Early diagnosis and multidisciplinary management—including hormonal, psychological, bone health, and fertility preservation support—are essential to mitigate morbidity and optimize well-being. Patient education, peer support, and shared decision-making are integral components of holistic care in reproductive medicine departments.

# 卵巢早衰（POF）治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

• •激素替代治疗（HRT）：适用于40岁以下、无禁忌证者（如乳腺癌、血栓病史）。含雌孕激素周期序贯方案，含基础检查（性激素六项、AMH、盆腔超声、骨密度）：¥1,200–¥2,800/年；中档进口制剂（如克龄蒙）年药费约¥3,600–¥5,200；高端个体化缓释贴剂+监测年总费用¥6,500–¥9,800。
• •DHEA辅助治疗：需检测肾上腺功能后启用，3个月为一疗程，含DHEA检测+用药指导：¥1,800–¥3,200/疗程。
• •中医辨证调理（针药结合）：需经生殖中医师评估，含舌脉诊、中药颗粒剂、耳穴压豆及艾灸理疗，12周为一周期：¥4,200–¥7,500/周期。

二、手术/介入方案

卵巢早衰属不可逆性卵泡耗竭，目前无根治性手术或介入治疗手段。腹腔镜下卵巢打孔术、干细胞卵巢内注射等均缺乏循证依据，不推荐于正规三甲生殖中心开展，亦无医保报销及规范收费标准。

三、特殊复杂情况处理

• •合并自身免疫性疾病（如Addison病、甲状腺炎）：加用免疫调节治疗（如小剂量糖皮质激素），年综合管理费¥8,000–¥15,000；
• •已绝经且有生育需求者：需行供卵试管婴儿（IVF-ET），全流程（含供者筛查、胚胎培养、移植、黄体支持）¥68,000–¥125,000/周期。

四、方案快速选择指南

• •预算有限、以缓解症状为主：首选国产HRT+基础监测（¥2,000–¥4,000/年）；
• •年轻未育、AMH<0.5ng/mL但仍有窦卵泡：联合DHEA+促性腺激素微刺激方案（¥12,000–¥18,000/尝试周期）；
• •明确无自发排卵、强烈生育诉求：直接进入供卵IVF路径，避免无效保守治疗耗时耗资。